COL18A1 and non-small cell lung carcinoma: In summary, our study revealed that rh‐endostatin plus camrelizumab and chemotherapy has promising efficacy and safety profile in the first‐line treatment of advanced‐stage NSCLC, which indicated that this regimen could be a potential treatment option for advanced‐stage NSCLC patients.